FDA ruling on Eliquis postponed Pfizer, Bristol: FDA ruling on Eliquis postponed Mar 1 11:07 AM US/Eastern TRENTON, N.J. (AP) - Drugmakers Pfizer Inc. and Bristol-Myers Squibb Co. say federal regulators have pushed back the deadline for deciding whether to approve their highly touted experimental anticlotting drug. The companies say the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis (El'-eh-kwiss). That's three months later than originally scheduled. The drugmakers, both based in New York, say that after submitting their original application for approval of the drug, they sent the FDA additional information from patient studies. The new information will require more time for review. Eliquis is one of a handful of drugs recently approved or under review for preventing heart attacks and strokes.